APA (7th ed.) Citation

Foley, A., Quijano-Roy, S., Collins, J., Straub, V., Deconinck, N., Mercuri, E., . . . Bönnemann, C. (2011). P2.5 The identification of a viable outcome measure in the collagen VI myopathies promotes progress toward clinical trials. Neuromuscular Disorders, 21(9/10), 662. https://doi.org/10.1016/j.nmd.2011.06.828

Chicago Style (17th ed.) Citation

Foley, A.R, et al. "P2.5 The Identification of a Viable Outcome Measure in the Collagen VI Myopathies Promotes Progress Toward Clinical Trials." Neuromuscular Disorders 21, no. 9/10 (2011): 662. https://doi.org/10.1016/j.nmd.2011.06.828.

MLA (9th ed.) Citation

Foley, A.R, et al. "P2.5 The Identification of a Viable Outcome Measure in the Collagen VI Myopathies Promotes Progress Toward Clinical Trials." Neuromuscular Disorders, vol. 21, no. 9/10, 2011, p. 662, https://doi.org/10.1016/j.nmd.2011.06.828.